Published in J Nucl Med on March 01, 2001
The influence of wire localisation for non-palpable breast lesions on visualisation of the sentinel node. Eur J Nucl Med Mol Imaging (2006) 2.24
Sentinel lymph node accumulation of Lymphoseek and Tc-99m-sulfur colloid using a "2-day" protocol. Nucl Med Biol (2009) 1.05
Sentinel lymph node mapping of breast cancer via intradermal administration of Lymphoseek. Nucl Med Biol (2007) 0.99
Lymphoscintigraphy and triangulated body marking for morbidity reduction during sentinel node biopsy in breast cancer. Int Semin Surg Oncol (2005) 0.80
(99m)Tc-dextran lymphoscintigraphy can detect sentinel lymph node in breast cancer patients. Exp Ther Med (2014) 0.78
The use of isotope injections in sentinel node biopsy for breast cancer: are the 1- and 2-day protocols equally effective? Springerplus (2015) 0.75
Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg (2001) 5.94
Radiometric detection of the metabolic activity of Mycobacterium tuberculosis. J Nucl Med (1975) 5.30
Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res (2001) 4.87
Sentinel lymph node biopsy: is it indicated in patients with high-risk ductal carcinoma-in-situ and ductal carcinoma-in-situ with microinvasion? Ann Surg Oncol (2000) 3.75
Automated detection of Haemophilus influenzae. Appl Microbiol (1973) 3.16
Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer (1997) 2.81
Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography. Cancer Res (1998) 2.55
A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index. Clin Cancer Res (1998) 2.43
Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol (1999) 2.38
Sentinel lymph node biopsy in breast cancer: initial experience at Memorial Sloan-Kettering Cancer Center. J Am Coll Surg (1998) 2.32
Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst (1991) 2.19
Imaging transgene expression with radionuclide imaging technologies. Neoplasia (2000) 2.03
Intradermal radiocolloid and intraparenchymal blue dye injection optimize sentinel node identification in breast cancer patients. Ann Surg Oncol (1999) 2.02
Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol (1989) 2.00
Diagnostic and prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol (2002) 1.96
Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia. J Nucl Med (1999) 1.95
[18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab (1999) 1.90
The case for and technique of heterotopic liver grafting. Transplant Proc (1979) 1.87
Small-cell carcinoma of the gastrointestinal tract: a retrospective study of 64 cases. Br J Cancer (2004) 1.75
Bone metastases from thyroid carcinoma: a histopathologic study with clinical correlates. Arch Pathol Lab Med (2000) 1.74
Four-dimensional (4D) PET/CT imaging of the thorax. Med Phys (2004) 1.74
Quantitative imaging of iodine-124 with PET. J Nucl Med (1996) 1.69
Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med (1998) 1.67
Lessons learned from 500 cases of lymphatic mapping for breast cancer. Ann Surg (1999) 1.67
Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer. J Clin Oncol (2003) 1.63
Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred forty-six patients. Thyroid (2000) 1.59
111Indium-diethylenetriamine pentaacetic acid cerebrospinal fluid flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases. Neurology (1998) 1.59
Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab (2000) 1.59
Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J Clin Oncol (1998) 1.56
Phase and amplitude binning for 4D-CT imaging. Phys Med Biol (2007) 1.52
Fulminant hepatic failure after Lepiota mushroom poisoning. J Hepatol (1993) 1.51
Radiopharmacology of a simplifield technetium-99m-colloid preparation for photoscanning. J Nucl Med (1966) 1.49
FDG-PET standardized uptake values in normal anatomical structures using iterative reconstruction segmented attenuation correction and filtered back-projection. Eur J Nucl Med (2001) 1.49
Effect of respiratory gating on reducing lung motion artifacts in PET imaging of lung cancer. Med Phys (2002) 1.48
Complementarity of blue dye and isotope in sentinel node localization for breast cancer: univariate and multivariate analysis of 966 procedures. Ann Surg Oncol (2001) 1.44
In vitro complex formation and biodistribution of mouse antitumor monoclonal antibody in cancer patients. J Nucl Med (1989) 1.43
Localization of 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy. J Clin Invest (1983) 1.42
Sentinel lymph node biopsy after percutaneous diagnosis of nonpalpable breast cancer. Radiology (1999) 1.42
Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJR Am J Roentgenol (1988) 1.41
Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts. J Clin Oncol (1994) 1.41
In vivo fate of monoclonal antibody B72.3 in patients with colorectal cancer. J Nucl Med (1990) 1.41
Triumph over mischance: a role for nuclear medicine in gene therapy. J Nucl Med (1997) 1.41
Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg (1999) 1.41
Statistical issues in analysis of diagnostic imaging experiments with multiple observations per patient. Radiology (2001) 1.40
Quantitative bone metastases analysis based on image segmentation. J Nucl Med (1997) 1.36
Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J Clin Oncol (1993) 1.35
Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments. Cancer Treat Rep (1984) 1.35
Quantitation of respiratory motion during 4D-PET/CT acquisition. Med Phys (2004) 1.35
3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study. Int J Oncol (1998) 1.35
Dimensions of the normal adult spleen scan and prediction of spleen weight. J Nucl Med (1971) 1.33
Highest isotope count does not predict sentinel node positivity in all breast cancer patients. Ann Surg Oncol (2001) 1.32
Patterns of abnormal FDG uptake by various histological types of non-small cell lung cancer at initial staging by PET. Eur J Nucl Med (2001) 1.31
Quantitative analysis of antibody localization in human metastatic colon cancer: a phase I study of monoclonal antibody A33. J Clin Oncol (1990) 1.28
Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg (1985) 1.27
Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts. Clin Cancer Res (2001) 1.26
Midazolam changes cerebral blood flow in discrete brain regions: an H2(15)O positron emission tomography study. Anesthesiology (1997) 1.25
A general approach to the non-invasive imaging of transgenes using cis-linked herpes simplex virus thymidine kinase. Neoplasia (1999) 1.25
Imaging of melanoma with L-131-labeled monoclonal antibodies. J Nucl Med (1983) 1.24
Effects of obstetrician gender on communication and patient satisfaction. Obstet Gynecol (1999) 1.23
Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases. J Clin Endocrinol Metab (2013) 1.21
Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol (1996) 1.21
Predicting tumor response in patients with colorectal hepatic metastases. Ann Surg (1985) 1.20
The radionuclide ejection fraction: a comparison of three radionuclide techniques with contrast angiography. J Nucl Med (1977) 1.18
Survival from locally invasive or widespread neuroblastoma without cytotoxic therapy. J Clin Oncol (1996) 1.18
Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid (2001) 1.17
Dynamic contrast enhanced-MRI for the detection of pathological complete response to neoadjuvant chemotherapy for locally advanced rectal cancer. Eur Radiol (2011) 1.17
A trend analysis of the relative value of blue dye and isotope localization in 2,000 consecutive cases of sentinel node biopsy for breast cancer. J Am Coll Surg (2001) 1.17
The pharmacology of monoclonal antibodies. Ann N Y Acad Sci (1987) 1.15
Radiolabeled monoclonal anti-tumor antibodies in diagnosis and therapy. J Nucl Med (1985) 1.14
Pilot clinical trial of 5-[125I]iodo-2'-deoxyuridine in the treatment of colorectal cancer metastatic to the liver. J Nucl Med (1996) 1.13
The role of staging laparoscopy in hepatobiliary malignancy: prospective analysis of 401 cases. Ann Surg Oncol (2003) 1.12
Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo. Cancer Res (2001) 1.12
Using positron emission tomography with [(18)F]FDG to predict tumor behavior in experimental colorectal cancer. Neoplasia (2001) 1.11
Clinical liver heterotopic (auxiliary) transplantation. Surgery (1973) 1.11
Implementation of a Monte Carlo dosimetry method for patient-specific internal emitter therapy. Med Phys (1997) 1.10
Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J Clin Oncol (2001) 1.10
Myocardial perfusion abnormalities in patients with hypertrophic cardiomyopathy: assessment with thallium-201 emission computed tomography. Circulation (1987) 1.09
Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography. Mol Imaging Biol (2006) 1.09
An unusual cause of partial ETT obstruction. Anesthesiology (1998) 1.09
Metabolic imaging of human extremity musculoskeletal tumors by PET. J Nucl Med (1988) 1.08
Positron emission tomography imaging for herpes virus infection: Implications for oncolytic viral treatments of cancer. Nat Med (2001) 1.08
Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res (1998) 1.07
Use of PET to monitor the response of lung cancer to radiation treatment. Eur J Nucl Med (2000) 1.07
Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol (1994) 1.06
Antibody response to murine anti-GD2 monoclonal antibodies: correlation with patient survival. Cancer Res (1994) 1.05
Visualization of the placenta by radioisotope photoscanning using technetium-99m-labeled albumin. Am J Obstet Gynecol (1965) 1.04
Detection of bony metastases of androgen-independent prostate cancer by PET-FDG. Nucl Med Biol (1996) 1.03
Effect of blood transfusion on outcome after pancreaticoduodenectomy for exocrine tumour of the pancreas. Br J Surg (2007) 1.03
Radiofrequency ablation in the management of liver metastases from breast cancer. AJR Am J Roentgenol (2007) 1.02
Radioimmunodetection in cancer identification. J Nucl Med (1992) 1.02
Fludeoxyglucose positron emission tomography in the diagnosis of giant cell arteritis. Arch Intern Med (2001) 1.02
The breast cancer patient with multiple sentinel nodes: when to stop? J Am Coll Surg (2001) 1.01
Perioperative complications influence recurrence and survival after resection of hepatic colorectal metastases. Ann Surg Oncol (2013) 1.01